 Neo-adjuvant pre-emptive cisplatin therapy invasive transitional cell carcinoma bladder pilot studies response rates intravenous cisplatin transitional cell carcinoma bladder definitive treatment West Midlands Urological Research Group WMURG Australian Bladder Cancer Study Group ABCSG randomised trials survival benefit neo-adjuvant intravenous cisplatin transitional cell carcinoma bladder trials target numbers patients West Australia similar treatment protocols eligibility criteria overview analysis total number patients treatment group control group differences overall result difference survival control patients odds ratio control groups chemotherapy groups patients confidence interval odds ratio wide clear evidence worthwhile benefit neo-adjuvant cisplatin approach study combination treatments activity metastatic disease